Get the Stockscreener App
0.6674
13.93%
0.0816
Cognition Therapeutics Inc stock is traded at $0.6674, with a volume of 4.03M.
It is up +13.93% in the last 24 hours and up +113.70% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.5858
Open:
$0.5555
24h Volume:
4.03M
Relative Volume:
0.57
Market Cap:
$41.37M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.8448
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-20.55%
1M Performance:
+113.70%
6M Performance:
-7.69%
1Y Performance:
-25.84%
1-Day Range:
$0.5555
$0.6996
1-Week Range:
$0.5555
$0.8499
52-Week Range:
$0.2223
$1.29
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.6674 | 36.32M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - jammulinksnews.com
Does Cognition Therapeutics Inc. stock perform well during market downturnsEntry Signal Growth Plan That Work - jammulinksnews.com
What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - jammulinksnews.com
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - TipRanks
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Beginner Investor Data Feed With High Returns - jammulinksnews.com
What makes Cognition Therapeutics Inc. stock price move sharplyBeginner Investor Insights Backed By Experts - jammulinksnews.com
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance
Published on: 2025-07-29 20:05:06 - metal.it
Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times
How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it
Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire
Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionMassive wealth growth - jammulinksnews.com
How volatile is Cognition Therapeutics Inc. stock compared to the marketMaximize returns with disciplined trading approaches - jammulinksnews.com
Is it the right time to buy Cognition Therapeutics Inc. stockMarket-crushing profits - jammulinksnews.com
What institutional investors are buying Cognition Therapeutics Inc. stockPowerful growth strategies - jammulinksnews.com
What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional
Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug By Investing.com - Investing.com India
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Cognition Therapeutics Publishes Proteomic Analysis of Zervimesine's Protective Effects on Neurons and Synapses in Alzheimer's Disease - AInvest
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):